Global Partners L.P. (GLP)
NYSE NYSE Primary 
Novo Nordisk Is Ready to Ramp Up GLP-1 Manufacturing Following $11B Factory Deal
Novo has handed Wolff one of the most complex jobs in all of pharmaceuticals.
Viking Therapeutics: Holiday Gift
Viking Therapeutics has seen a significant drop, losing 50% in value since late October, despite positive news and promising GLP-1 drug developments. The biotech's oral GLP-1 candidate VK2735 showed impressive weight loss results and tolerability, with potential advantages over current weekly injectable treatments. Concerns about manufacturing costs and scalability exist, but Viking's strong pipeline and market potential in obesity make it a compelling investment.
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has begun dosing in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). The Study is designed mainly to determine whether Lexaria's proprietary DehydraTECH technology improves the safety and effectiveness of existing GLP-1 drugs.
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
Recent sales of a little-known stock, Madrigal Pharmaceuticals NASDAQ: MDGL, could bode well for Novo Nordisk A/S NYSE: NVO. The pharma industry giant has seen explosive sales growth for its GLP-1 agonist drug, semaglutide.
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
Successful Completion of All Planned Implants in GLP Study enVVe Delivery System Demonstrates Consistent Performance Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave of implants for shorter-term subjects in its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The successful completion of all planned implants in the GLP study, including both long-term and short-term subjects, completes a critical phase of the study.
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide KELOWNA, BC / ACCESSWIRE / December 9, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of a contract research organization ("CRO") to design and execute a human pilot study evaluating DehydraTECH-liraglutide against Saxenda® injectable liraglutide. As reported on November 20th in Lexaria's 12-week rodent study with unlimited food available, DehydraTECH-processed liraglutide - administered orally - demonstrated a 5.88% weight reduction and 11.54% blood sugar reduction compared to baseline.
Structure CEO on the competitive landscape for oral GLP-1 drugs
Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings.
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?
There's a growing number of companies entering the weight loss space, focusing on GLP-1 drugs which can be game changers for their businesses. And one of them is Viking Therapeutics (VKTX -2.70%), which has a promising GLP-1 treatment in development that investors are hopeful will generate billions in revenue for the modestly sized healthcare company.
Fmr. FDA Commissioner on how Trump could impact GLP-1 industry
Dr. Scott Gottlieb joins 'Fast Money' to talk how a Trump administration could impact the GLP-1 drug industry.
Millions more Americans might get access to GLP-1 drugs
A new proposal by the Biden administration would see obesity drugs covered under Medicare and Medicaid. Transcript: Conway Gittens: The Dow and the S&P 500 closed at fresh record highs on Tuesday as investors tried to pick winners and losers in Donald Trump's tariff plans.
Biden administration plans to expand coverage of GLP-1 drugs for Americans with Medicare & Medicaid
CNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs for Americans with Medicare and Medicaid.
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more GLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come KELOWNA, BC / ACCESSWIRE / November 26, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following strategic update. Today's GLP-1 drug market consists primarily of semaglutide (Wegovy®, Ozempic®, and Rybelsus®), owned by Novo Nordisk®; and tirzepatide (Zepbound®, Mounjaro®), owned by Eli Lilly™.
